Title: Should You Still Invest in ABT Stock Following a 10% Surge in a Week?
Abbott (NYSE: ABT) recently reported its Q4 earnings, with revenues barely falling short and profits meeting expectations. The company reported revenues of $10.97 billion and earnings of $1.34 per share, surpassing the consensus estimates by a small margin. The medical devices segment saw significant growth, while diagnostics sales showed a marginal decline.
Looking ahead to Q1, Abbott's projection fell short of market predictions. Despite this, ABT stock has skyrocketed over 10% in a week, largely due to optimism surrounding its diabetes products and improving profitability in 2024. As of now, ABT stock has gained 15% since the start of 2024, however, it has underperformed the S&P 500 index, which has seen a 28% growth during the same period.
Those seeking stable returns with minimal volatility can consider the High-Quality portfolio, which has surpassed the S&P 500 index and delivered over 91% returns since its inception.
Abbott's Q4 revenue of $10.97 billion marked a 7.2% year-over-year increase. The medical device segment reported an impressive 13.7% surge, while the nutrition segment saw a growth of 4.5%. The pharmaceuticals segment also experienced a 3.8% rise. However, this rise was partially offset by a 0.6% decline in diagnostics sales.
The medical devices segment's growth can be attributed to the growing demand for Abbott's FreeStyle Libre, which saw a 20.1% surge in Q4 sales. Diabetes products, along with offerings such as Navitor, TriClip, and Amulet, have fueled the segment's growth.
Abbott's operating margin remained consistent at 17.4% in Q4, while earnings saw a 12.6% year-over-year increase. For 2025, Abbott anticipates a 7.5% to 8.5% rise in total revenue on an organic basis, and a 150 basis point improvement in operating margin. This growth, coupled with improved margins, implies a mid-range earnings growth of 10%.
While Q1 outlook fell below expectations, Abbott anticipates strong earnings growth for 2025. Additionally, ABT stock is currently trading at slightly below its average P/E ratio of 25x during the past three years, suggesting room for growth.
Abbott's peers show varied performance metrics. To gain a deeper understanding of the market landscape, you can explore Abbott's peer comparisons available on various platforms. Invest with Trefis' Market Beating Portfolios to capitalize on these insights and optimize your investment strategy.
Abbott's management mentioned that they are planning to conduct an assessment about the company's valuation, particularly focusing on the impacts of the revenue growth trends. Despite the slightly disappointing Q1 projections, analysts are still optimistic about Abbott's valuation, given the strong performance of its diabetes products and the promising outlook for 2025.
